Dendritic Cell Immunotherapy for Prostate Cancer

Q: Is the age restriction for this research limited to those below fifty-five?

<p>As per the regulations of this trial, only those 18 years old or above and below 65 are eligible for enrollment.</p>

Q: What health risks are associated with this treatment plan?

<p>Due to the <a href="https://www.withpower.com/clinical-trials/experimental">experimental</a> nature of this treatment, with limited evidence demonstrating safety and efficacy, its score is 1 on a scale from 1-3.</p>

Phase 1

Waitlist Available

Led By Johannes Vieweg, M.D.

Research Sponsored by National Center for Research Resources (NCRR)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

The patient has a histologic or clinically confirmed prostate adenocarcinoma (Stage D1-D3 metastatic with regional lymphatic, bone, visceral, or soft tissue metastases) excluding transitional cell and small cell carcinomas of prostate origin

The patient has adequate renal and hepatic function with serum creatinine < 2.5mg/dl and bilirubin < 2.0 mg/dl

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing the feasibility and safety of administering escalating doses of tumor RNA transfected dendritic cells to patients with metastatic prostate cancer, in order to evaluate the ability of the cells to induce tumor-specific immune responses.

Who is the study for?

This trial is for men with metastatic prostate cancer (stages D1-D3) who have a life expectancy over 6 months, good physical health, and normal blood, kidney, liver, and coagulation tests. They can continue hormone therapy but must stop other treatments before joining. Men with autoimmune diseases, serious illnesses like severe heart or lung conditions, active infections including HIV or hepatitis, another cancer type besides skin cancer or superficial bladder cancer cannot join.Check my eligibility

What is being tested?

The study is testing the safety of a new treatment where patients' own immune cells (dendritic cells) are modified in the lab to attack their prostate cancer by using RNA from their tumors. The goal is to see if these modified cells can boost the body's ability to fight the tumor and improve patient outcomes.See study design

What are the potential side effects?

Potential side effects aren't specified here but generally could include reactions at injection sites, flu-like symptoms such as fever and chills due to immune activation; fatigue; possible autoimmunity since this involves stimulating the immune system.